Holen Sie sich die Stockscreener-App
0.8197
0.17%
0.0048
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt XAIR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8245
Offen:
$0.8051
24-Stunden-Volumen:
6,258
Relative Volume:
0.00
Marktkapitalisierung:
$8.63M
Einnahmen:
$1.78M
Nettoeinkommen (Verlust:
$-58.35M
KGV:
-0.4998
EPS:
-1.64
Netto-Cashflow:
$-56.66M
1W Leistung:
-4.73%
1M Leistung:
-20.59%
6M Leistung:
-63.46%
1J Leistung:
+227.87%
1-Tages-Spanne:
$0.8051
$0.8225
1-Wochen-Bereich:
$0.7576
$0.8706
52-Wochen-Spanne:
$0.1521
$4.78
Beyond Air Inc Stock (XAIR) Company Profile
Firmenname
Beyond Air Inc
Sektor
Branche
Telefon
516-665-8200
Adresse
900 STEWART AVENUE, GARDEN CITY, NY
Compare XAIR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XAIR
Beyond Air Inc
|
0.8197 | 9.04M | 1.78M | -58.35M | -56.66M | -1.64 |
|
ABT
Abbott Laboratories
|
110.14 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
356.58 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.86 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.38 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Beyond Air Inc Stock (XAIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Eingeleitet | D. Boral Capital | Buy |
| 2024-06-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-28 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-28 | Eingeleitet | Truist | Buy |
| 2019-10-22 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Beyond Air Inc Aktie (XAIR) Neueste Nachrichten
Beyond Air terminates NeuroNOS sale talks with XTL Biopharmaceuticals By Investing.com - Investing.com Canada
Beyond Air (XAIR) Buy Rating Reaffirmed by D. Boral Capital | XA - GuruFocus
Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - Bitget
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - The Manila Times
Beyond Air drops NeuroNOS sale, rethinks neurological and cancer plans - Stock Titan
New Highs: Is Beyond Air Inc stock a falling knife or bargain buy2025 Biggest Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Technical Analysis: Can Beyond Air Inc continue delivering strong returns2025 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Insider Sell: Will Beyond Air Inc benefit from geopolitical trends2025 Short Interest & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Swing Trade: Is Beyond Air Inc stock a buy or sellWeekly Trading Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies - Finviz
12 Best NASDAQ Penny Stocks to Buy According to Analysts - Insider Monkey
Published on: 2026-03-02 20:03:07 - baoquankhu1.vn
Bull Bear: Can Beyond Air Inc deliver consistent EPS growthJuly 2025 Setups & Stock Portfolio Risk Management - baoquankhu1.vn
XAIR Should I Buy - Intellectia AI
XAIR PE Ratio & Valuation, Is XAIR Overvalued - Intellectia AI
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval - Yahoo Finance
Earnings Beat: What is the PEG ratio of Beyond Air IncJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
XAIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressi - GuruFocus
Balyasny Asset Management L.P. Increases Stake in Beyond Air Inc - GuruFocus
Beyond Air comments on review of high-dose nitric oxide therapy - Investing.com Nigeria
Beyond Air (XAIR) Highlights Potential of High-Dose Inhaled Nitr - GuruFocus
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - The Manila Times
Beyond Air, Inc. Highlights Comprehensive Review on High-Dose Inhaled Nitric Oxide as Potential Antimicrobial Therapy for Respiratory Infections - Quiver Quantitative
Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - Bitget
High-dose inhaled gas shows promise against tough lung infections - Stock Titan
Published on: 2026-02-18 22:24:05 - baoquankhu1.vn
Analysis Recap: Is Beyond Air Inc showing insider buyingBuy Signal & AI Driven Stock Reports - baoquankhu1.vn
Aug Outlook: How liquid is Beyond Air Inc stockTrade Entry Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
XAIR Technical Analysis & ETF Price Forecast - Intellectia AI
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Intellectia AI
MSN Money - MSN
Leishen Energy's FY2025 Financial Results Analysis - Intellectia AI
Analyst Warns: Failure of NeuroNOS Acquisition Could Pressure Beyond Air’s Strategy, Finances, and Stock Price - TipRanks
1 Reason I'd Buy Intuitive Surgical Stock and Never Sell - AOL.com
Beyond Air, Inc. (NASDAQ:XAIR) Q3 2026 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Beyond Air Q3 2026 sees revenue growth and cost cuts - Investing.com Nigeria
XAIR Technical Analysis & Stock Price Forecast - Intellectia AI
XAIR Maintains Revenue Outlook for Fiscal Year Ending 2026 - GuruFocus
Beyond Air (XAIR) Reports Strong Q3 Revenue With Promising Growt - GuruFocus
Beyond Air Shares Rise Intraday After Q3 FY2026 Revenue More Than Doubles; Loss Narrows on Cost Cuts - AlphaStreet News
Beyond Air Reports Strong Q3 Growth and Funding Extension - TipRanks
Beyond Air, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Beyond Air, Inc. SEC 10-Q Report - TradingView
XAIR: Quarterly revenue doubled and net loss narrowed, but additional funding is needed within a year - TradingView
Beyond Air XAIR Q3 2026 Earnings Call Transcript - The Globe and Mail
XAIR: Revenue up 105% year-over-year, with strong cost controls and global LungFit PH expansion - TradingView
Beyond Air Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
BEYOND AIR INC (NASDAQ:XAIR) Posts Revenue Beat, Reaffirms Guidance in Q3 2026 - ChartMill
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Finanzdaten der Beyond Air Inc-Aktie (XAIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):